Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with <i>SLC45A3‐ERG</i> gene rearrangement and an unfavorable clinical course

23 Jul 2012

Abstract excerpt

The majority of prostate cancer harbors recurrent gene fusions involving ETS transcription factors, most commonly ERG. The second most common 5' fusion partner after TMPRSS2 is SLC45A3. The aim of our study was to quantify the protein expression of ERG, TMPRSS2 and SLC45A3 in prostate cancer to assess for diagnostic or prognostic utility. Six hundred and forty consecutive prostate cancer cases in tissue...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Genomics and Chromatin Dynamics
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22821757
DOI: 10.1002/ijc.27733

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with <i>SLC45A3‐ERG</i> gene rearrangement and an unfavorable clinical coursePMID 22821757Read ↗

Molecular Diagnosis of Prostate Cancer: <i>PCA3</i> and <i>TMPRSS2:ERG</i> Gene FusionSemantic proximity Read ↗

Delineation of <i>TMPRSS2-ERG</i> Splice Variants in Prostate CancerSemantic proximity Read ↗

<i>TMPRSS2:ERG</i> fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosisSemantic proximity Read ↗

Clinical Applications of Novel ERG Immunohistochemistry in Prostate Cancer Diagnosis and ManagementSemantic proximity Read ↗

Prevalence of TMPRSS2–ERG and SLC45A3–ERG gene fusions in a large prostatectomy cohortSemantic proximity Read ↗

SLC45A3-ELK4 Is a Novel and Frequent Erythroblast Transformation–Specific Fusion Transcript in Prostate CancerSemantic proximity Read ↗

<i>TMPRSS2:ETV4</i> Gene Fusions Define a Third Molecular Subtype of Prostate CancerSemantic proximity Read ↗

<i>TMPRSS2</i> : <i>ERG</i> Fusion Identifies a Subgroup of Prostate Cancers with a Favorable PrognosisSemantic proximity Read ↗

A Fluorescence <i>In situ</i> Hybridization Screen for E26 Transformation–Specific Aberrations: Identification of DDX5-ETV4 Fusion Protein in Prostate CancerSemantic proximity Read ↗

ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.Semantic proximity Read ↗

Fusion in the ETS gene family and prostate cancerSemantic proximity Read ↗

Mapping Isoform Abundance and Interactome of the Endogenous TMPRSS2-ERG Fusion Protein with Orthogonal Immunoprecipitation-Mass Spectrometry AssaysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.